Search Results for: Pharma: Other News to Note
-
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
Other, sub-Saharan countries are at the very beginning...They wouldn't have to do this in a mature market, or in some of the other emerging markets, whether it's about education, or a secure distribution, or even pharmacovigilance, which they will have to build their own systems forBy Randy Osborne | BioWorld International | Wednesday, February 6, 2013 -
Pharma: Other News To Note
The transaction is subject to approval by Covidien's board, and the separation is expected to be complete at the end of the second quarter of 2013...The FDA granted orphan drug designation to the product for retinitis pigmentosaBioWorld Today | Tuesday, February 5, 2013 -
Pharma: Other News To Note
Shire plc, of Dublin, Ireland, said it reached agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S...sales and marketing practices relating to Adderall XR (mixed amphetamine salts), Vyvanse (lisdexamfetamine dimesylate) and Daytrana (methylphenidate transdermal systemBioWorld Today | Monday, February 4, 2013 -
Other News To Note
The restricted stock units vest over three years, and each is subject to terms of the company's 2012 equity incentive plan...Seattle Genetics Inc., of Bothell, Wash., reported that Health Canada has approved for marketing Adcetris (brentuximab vedotin), to treat: Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates...Valeant Pharmaceuticals International Inc., of MontrealBioWorld Today | Monday, February 4, 2013 -
Pharma: Other News To Note
The company brought patent infringement action in April 2010 against generic firm Watson Laboratories Inc., of Parsippany, N.Y., (now known as Actavis) after Watson applied to the FDA to market a generic version of RapamuneBioWorld Today | Friday, February 1, 2013 -
Pharma: Other News To Note
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the FDA's Pulmonary-Allergy Drugs Advisory Committee recommended that clinical data included in a new drug application provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysemaBioWorld Today | Thursday, January 31, 2013 -
'Safari,' So Good: Africa Tracks to Become Pharma Hot Spot
Other, sub-Saharan countries are at the very beginning...They wouldn't have to do this in a mature market, or in some of the other emerging markets, whether it's about education, or a secure distribution, or even pharmacovigilance, which they will have to build their own systems forBy Randy Osborne | BioWorld Today | Thursday, January 31, 2013 -
Pharma: Other News To Note
SOHO Industri Pharmasi for the registration and commercialization of Caldolor (ibuprofen) injection, which is used to treat pain and fever in the hospital setting...Merck Serono, of Geneva, a division of Merck KGaA, and the Feinstein Institute for Medical Research, the research division of the North Shore-Long Island Jewish Health System in New York, said they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE...The program will focus on the use of antibodiesBioWorld Today | Wednesday, January 30, 2013 -
Other News To Note
BioCryst's chimpanzee study had been designed to determine if nontoxic doses of BCX5191 would have a potent antiviral effect...Cerulean Pharma Inc., of Cambridge, Mass., said preclinical data showed that CRLX101 in combination with Avastin (bevacizumab, Roche AG) inhibited tumor growth and improved survival vs...Lee's will have an option to negotiate for commercial rights in ChinaBioWorld Today | Wednesday, January 30, 2013 -
Other News To Note
to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor...In other news, Novartis said the FDA approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemiaBioWorld International | Wednesday, January 30, 2013 -
Pharma: Other News To Note
Ltd., of South Kora, for exclusive distribution rights to Hanmi's new drug application, currently under FDA review, for esomeprazole strontium delayed-release capsules...Hanmi filed the application pursuant to the 505(b)(2) pathway with data showing comparative bioequivalence of its drug to Nexium (esomeprazole magnesium delayed-release capsules, AstraZeneca plcBioWorld Today | Tuesday, January 29, 2013 -
Pharma: Other News To Note
Through a two-year collaboration, AstraZeneca will add 250,000 high-quality compounds to LDC's internal screening collection to pursue projects in the areas of oncology, neuroscience, respiratory and inflammation, cardiovascular, gastrointestinal and infection research...AstraZeneca then will have a preferred right to obtain a license for preclinical and clinical development and commercializationBioWorld Today | Monday, January 28, 2013 -
Pharma: Other News To Note
Watson Pharmaceuticals Inc., of Parsippany, N.J., changed its name to Actavis IncBioWorld Today | Friday, January 25, 2013 -
Pharma: Other News To Note
Novartis AG, of Basel, Switzerland, said the FDA expanded the approved use of Exjade (deferasirox) to treat patients ages 10 and older who have chronic iron overload resulting from nontransfusion-dependent thalassemia, a genetic blood disorder...The FDA also is authorizing the marketing of FerriScan as an imaging companion diagnostic for Exjade to select patients for therapy and to manage therapy...Exjade previously gained approval for chronic iron overload due to blood transfusions in patients 2 andBioWorld Today | Thursday, January 24, 2013 -
Pharma: Other News To Note
Allergan Inc., of Irvine, Calif., said the FDA approved Botox (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medicationBioWorld Today | Wednesday, January 23, 2013 -
Other News To Note
Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations...The design of the trial later will be adapted, enabling it to separate into three separate personalized arms to test AZD0424 in different combinations alongside standard or other experimental treatmentsBioWorld International | Wednesday, January 23, 2013 -
Other News To Note
Toxicity experiments conducted to date revealed best-in-class potential with a greatly improved therapeutic index compared to other armed antibodies, due to an impressive safety profile, according to the company, which has opened a manufacturing facility in Nijmegen for the production of ADCs up to Phase III trials and early launchesBioWorld Today | Wednesday, January 23, 2013 -
Pharma: Other News To Note
The drug is expected to launch in Canada in the second quarterBioWorld Today | Tuesday, January 22, 2013 -
Aiming for NDA, Trius Pads Coffers with $30M Offering
Beyond Pfizer, other big pharma firms also could be interested...In other financings newsBy Jennifer Boggs | BioWorld Today | Tuesday, January 22, 2013 -
Pharma: Other News To Note
Ltd., of Osaka, Japan, inked a licensing deal to develop and market in Japan an oral formulation of a pediatric beta-blocker for the treatment of infantile hemangioma requiring a systemic therapyBioWorld Today | Friday, January 18, 2013
Category
Current Filters
- xNOT European Commission
Related Keywords
Categories
- x BioWorld Today (1870)
- x BioWorld International (384)
- x BioWorld Insight (45)
- x Bio Perspectives (27)
- x State of the Industry Report (5)
- x BioWorld Snapshots (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.